Patent ID: 9089618
Filing Date: 2015-07-28
Classification: A61K,B82Y,C07K,G01N

Abstract:
1. A method of treating a cancer that expresses MUC5ac comprising administering to a human subject with a cancer that expresses MUC5ac a humanized anti-MUC5ac monoclonal antibody or antigen-binding fragment thereof that binds to the same epitope as or competes for binding to MUC5ac with an antibody that comprises the light chain variable region CDR sequences CDR1 (SASSSVSSSYLY, SEQ ID NO:1); CDR2 (STSNLAS, SEQ ID NO:2); and CDR3 (HQWNRYPYT, SEQ ID NO:3); and the heavy chain variable region CDR sequences CDR1 (SYVLH, SEQ ID NO:4); CDR2 (YINPYNDGTQYNEKFKG, SEQ ID NO:5) and CDR3 (GFGGSYGFAY, SEQ ID NO:6), wherein the anti-MUC5ac antibody is conjugated to at least one therapeutic agent.